Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- 2hPG Recommended for Predicting Cardiovascular Disease Mortality: Takeda Seminar
May 14, 2001
- DIAGNOSTIC NEWS IN BRIEF
May 7, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -3-
May 7, 2001
- GPMSP Guidelines for Medical Devices to Go into Effect in October
May 7, 2001
- Takara Shuzo's Dragon Genomics Starts Full Operation
May 7, 2001
- WORLD NEWS IN BRIEF
May 7, 2001
- MEDICAL DEVICE NEWS IN BRIEF
May 7, 2001
- Chugai Establishes Chugai Pharma France in Paris
May 7, 2001
- Identification of Genes Related to Medical Diseases Expected within 10 Years
May 7, 2001
- BULLETIN
May 7, 2001
- MTP to Independently Market Grtpa
May 7, 2001
- Multidrug Resistance Seen in 6.2% of Tuberculosis Patients
May 7, 2001
- Nikken Chemical to Codevelop Sustained-release hGH with InfiMed of the US
May 7, 2001
- Solidifing Business Base by Increasing Productivity: Mochida President
May 7, 2001
- Large Study on Antihypertensives Planned: CASE-J
May 7, 2001
- Kyorin Sets Up Its First Overseas Business Base in US
May 7, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
May 7, 2001
- FPMAJ Issues GL for Paper, Plastic Discrimination Labeling
May 7, 2001
- Key Points of New Criteria for Drug-or-Food Judgment
May 7, 2001
- Future of Japanese Firms Is Not Easy: Nihon Univ. Seminar
May 7, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…